Cell-Based Assays: World Industry and Market Prospects 2015-2025

LONDON, May 26, 2015 /PRNewswire/ --

Cellular testing for pharmaceuticals - how to discover that technology's commercial potential
What's the future of technologies for screening cells? Now discover those technological and commercial predictions from 2015. Stay ahead there for data, benefiting your influence. For those medical tests, you explore sales results, R&D, opportunities and revenue forecasts.

That new report by visiongain shows you what's possible for cell-based assays and related applications to aid drug discovery and development. Those R&D tools change pharma, opening new possibilities. Find out how, discovering predicted trends, progress and gains.

Use of cell lines in bioassays becomes more important. Read on, then, to explore cell assaying products and services for medicine, seeing how high their revenues can go.

Forecasts and other analysis showing potential revenues from those bioassays
That study's purpose is forecasting cell testing sales to 2025 at overall world, submarket and national level. Does our work answer every question? No, though it assesses those technologies for research and development, showing there the money and potential gains.

There avoid struggles to find information on bioassays. Hear what's possible. Besides revenue predictions, our new analysis shows recent results, growth rates and market shares.

The new survey gives you 63 tables, 40 charts and three interviews with companies. So help your research, analyses and decisions now, also benefiting your authority and reputation for technological and commercial insight.

And the following sections explain how that investigation helps your work.

Predictions for the cellular assays market and its segments - assess sales prospects
What potential does that biomedical industry hold? And what secrets underpin its progress? Discover in our report overall world revenue to 2025 for cell assays, with discussions.

Also find individual revenue predictions from 2015 for submarkets there, at world level:

• Products
• Services

And get further revenue breakdown, from 2015, by application:

• Drug discovery
• ADME (absorption, distribution, metabolism, excretion)
• Basic research.

To see a report overview please email Sara Peerun on [email protected]

There assess revenue expansion, hearing where you could gain. Those uses include toxicity testing. See what's possible and investigate competition among developers and producers of cellular tests. You explore products, services, emerging technologies and rising sales.

That work also divides its overall world market into geographical revenue predictions.

Sales in leading national markets - what demand for medical cell assaying?
Our analyses also show you individual revenue forecasts to 2025 for 11 leading countries:

• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (EU5 countries), also with an overall European Union prediction
• Brazil, Russia, India and China (BRIC nations).

There you find countries with highest revenues, demand and potential increases in cell assay use and sales. And you understand competitors, needs and opportunities. That way you explore trends, progress and potentials, discovering what gains the future holds.

Also how do events, challenges and advances in technology affect that bioassays sector? Our study explains. It discusses progress, policies and trends influencing cellular assaying, helping you stay ahead in knowledge.

Forces affecting developers and producers of those drug discovery and development tools
The report explains issues, operations and events affecting that market from 2015. Those forces influencing companies developing, making and selling those systems include these:

• Uses in drug discovery, validating targets and lead profiling - including 2D and 3D bioassaying systems
• Platforms using high throughput screening (HTS) for improved testing efficiency
• Stem cells (inc. IPSCs) to extend molecular screening, esp. in toxicology studies, and other cell lines for pharma in vitro assays
• Systems using biochemical assays, GPCRs (G-protein-coupled receptors) and label-free methods
• Applications in developing biological drugs
• Contract and clinical research organisations (CROs) in that early-stage drug development.

And you explore these trends and influences, among others:

• Lead identification, target validation, primary, secondary and ADME screening
• Cell assaying equipment, kits, consumables and disposables
• Detection technology, microplate readers, microfluidics and flow cytometry, inc. assay miniaturisation and automation
• Multiplexing to improve efficiency in studying biological materials
• Cell viability and mitochondrial function assays in biomedical research
• High content screening (HCS) - optimising processes, increasing R&D pipeline efficiencies.

There you explore what progress, trends and prospects in those bioassays mean. And discover what benefits and what restricts participants in that industry, affecting its results.

To see a report overview please email Sara Peerun on [email protected]

Cell technologies for medical product development - top companies and 2018 market value
What does the future hold? Our study predicts that world market will reach $5.5bn in 2018.

Also, from 2015, outsourcing of cell-based assay processes will increase. There pharmaceutical clients and CROs will benefit. See how, discovering potentials.

And our new report examines activities of many companies, including these:

• Thermo Fisher Scientific
• PerkinElmer
• DiscoveRx
• GE Healthcare
• ProQinase
• Charles River Laboratories
• BD (Becton, Dickinson and Company).

There you find profiles of 18 prominent, rising and emerging companies. And see interviews with Cell Assay Innovations (CAI), Molecular Devices and CYTOO. Our survey explores issues affecting that industry's present and future.

Cell and tissue-based screening holds great potential. From this decade onwards, that market gives many opportunities. See where they lie and how that industry can perform.

Ways Cell-Based Assays: World Industry and Market Prospects 2015-2025 helps
In particular, our new investigation gives you this knowledge to benefit your research, analyses and planning:

• Revenues for cellular assays, to 2025, at world level and for five submarkets - explore prospects for design, production, sales, marketing, demand and spending
• Forecasts, to 2025, for 11 countries in the Americas, Europe and Asia - assess developed and developing national markets for demand and predicted revenues
• Prospects for established firms, rising companies and new entrants - examine product and service portfolios, results, strategies and outlooks for success
• Analyses of what stimulates and restrains that industry's participants - investigate challenges, strengths and competition affecting organisations' actions
• Interviews with authorities in that field - discover what participants from the industry think, say and do, helping you stay ahead in business knowledge.

Information there found nowhere else, benefiting your insight, work and influence
That study, done in-house by our UK-based analysts, gives independent knowledge. There gain competitive intelligence found only in that report, finding where progress and money lie.

With that data you're less likely to fall behind in information or miss opportunity. There see how you could save time and effort. And, through your choice, benefit your plans, decisions and authority, helping you gain competitive advantages.

Data to help your knowledge of pharma R&D - benefit from our study now
Our new analysis is for everyone investigating pharmaceutical research and development. There, for cellular assaying systems, you explore trends, results and revenue forecasts. So avoid missing out - please get that report here now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44(0)20-7336-6100

Or click on  http://goo.gl/gb2gpw

Companies and Other Organisations in the Study 

AstraZeneca
Axiogenesis
Bayer
BBC (British Broadcasting Corporation)
BD (Becton, Dickinson and Company)
BioCity
Biocroi
Biofocus
BioSeek
BioVision
BMG Labtech
CareFusion Corporation
Cell Assay Innovations (CAI)
Cellartis (Takara Bio)
Cellomics
Cellular Dynamics
Charles River Laboratories
Corning
Covance
CXR Biosciences
Cyprotex
CYTOO
Di Carlo Laboratory
DiscoveRx
Dr. Reddy's Laboratories
ESI BIO (BioTime)
Eurostars
Evotec
Fisher Scientific
Fluofarma
ForteBio
Foundation Top Institute Pharma
GE Healthcare
GenCell
General Electric (GE)
Harlan Laboratories
Imagen Biotech
InSphero
Janssen
Japan Institute of Biomedical Research
Jubilant Biosys
Lead Discovery Centre GmbH
Life Technologies Corporation
Marin Biologic Laboratories
Maxcyte
Merck & Co.
Molecular Devices
OcellO
PerkinElmer
Pharmaceutical Product Development (PPD)
Pharmacyclics
PharmaTimes
Princeton University
Promega
ProQinase
Quintiles
ReNeuron
ReproCELL
Roche
Sanofi
Seahorse Bioscience
SGS (Société Générale de Surveillance)
Solvo
SRU Biosystems
Swiss Federal Institute of Technology
SymCel
Syncom
The European Lead Factory (ELF)
The Innovative Medicines Initiative (IMI)
The National Health Service (NHS)
The Netherlands Cancer Institute
The Scientist Magazine
Thermo Electron
Thermo Fisher Scientific
Trinity College, Dublin
Tufts Center for the Study of Drug Development
UCB (Union Chimique Belge)
UCLA (University of California, Los Angeles)
UK Department of Health
University of Kyoto
University of Oxford
University of Zurich
US Congress
US FDA
Vala Sciences
WuXi

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44(0)20-7336-6100

SOURCE Visiongain